Nissan Chemical Industries Limited

Toudai Tlo, Ltd.

Japan Science and Technology Agency

The University of Tokyo

Fujitsu Corporation

National Institute for Materials Science

Yamasa Shoyu Kabushiki Kaisha

Theravalues Corporation

Kowa Company Limited

Ryozo Nagai

Takashi Kadowaki

Toshimasa Yamauchi

Junji Kamon

Masahiro Watanabe

Takumi Washio

Toshiaki Hisada

Seiryo Sugiura

Satoshi Kimura

Toru Suzuki

Yoshimasa Kadooka

Junichi Okada

Tetsushi Taguchi

Machiko Nakagawa

Kohei Hatanaka

Yasushi Imai

Katsuhito Fujiu

Tetsuya Kubota

Tetsuo Noda

Yasuyuki Katada

Tadashi Hashimoto

Naoto Kubota

Hiroyuki Morita

Atsuko Nakayama

Ichiro Manabe

Hironori Waki

Motoo Tomita

Yasuo Terauchi

Taro Kariya

Makoto Kuroo

Hirohisa Kato

Jyunji Nissan Chemical Industries Ltd Kamon

Jyunji Kamon

In a biological simulation apparatus, an operation unit represents a structure domain where tissues of a biological organ exist by a structure mesh model based on a Lagrange description and a fluid domain where fluid inside the biological organ exists by an ALE fluid mesh model based on an ALE description method. In a fluid-structure interaction simulation, the operation unit deforms the structure mesh model, and then deforms the ALE fluid mesh model so as to form no gap on a first interface between a domain where a site other than a certain site of the biological organ in the structure domain exists and the fluid domain or no overlap with the structure domain. The operation unit captures a position of a second interface between a domain where the certain site exists and the fluid domain by using the ALE fluid mesh model as a reference.

Biological simulation apparatus and biological simulation apparatus control method

Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.

Heart failure suppressing agent

A nickel-free stainless steel stent using a stainless steel which does not substantially contain Ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of Cr, from 0.97 to 2% by mass of Mo, and from 0.5 to 1% by mass of N, with the remainder being Fe, and optionally containing inevitable impurities.

Nickel-free stainless steel stent

The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

Adiponectin receptor and gene encoding the same

The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).

Insulin resistance improving agents

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

Method for treating arteriosclerosis

Using as an immunogen an oligopeptide containing a different portion of the amino acid sequence of isoform SM-1, SM-2 or SM-3 in smooth muscle myosin heavy chains, for example, the C-terminus amino acid sequence, antibodies capable of distinctly recognizing each isoform from other isoforms of the smooth muscle myosin heavy chains can be obtained. The antibodies are useful as reagents for tissue staining and also useful as diagnostic reagents of vascular disturbance or arteriosclerosis.

Antibody to smooth muscle myosin heavy chains

Growing community of inventors

Tokyo, Japan

Ryozo Nagai